SAREPTA

pharmaceuticals and pharmaceutical products for treating muscular dystrophy ((, infectious diseases and viruses that respond to ribonucleic acid (RNA)-based therapies )) ; pharmaceuticals comprising drugs based on Phosphorodiamidate Morpholino Oligomers technology platform, and drugs that modulate RNA expression

medical and scientific research services, namely, medical research; medical and scientific research services all in the field of muscular dystrophy, infectious diseases and viruses that respond to ribonucleic acid (RNA) modulation therapies